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characteristics that these putative trans-
porters would have to display if they existed.
As stated in our earlier contribution our
analysis leads us to conclude that these
transporters should be equilibrative, should
display Km values in the low millimolar
range, and in the case of highly-permeable
drugs should show high expression cou-
pled with high Kcat values. In addition, they
should preferably be expressed in both api-
cal and basolateral membranes, or have a
kinetically similar partner expressed in the
opposite membrane.
Thus, we maintain our conclusion that,
given the data available for human ATP-
binding cassette (ABC) transporters and
solute carriers (SLCs), it is unlikely that
these transporters account for all obser-
vations of cellular drug ﬂux. That said, an
increased understanding of drug transport
kinetics emanating from studies such as
[1,3] and novel experimental techniques
[17] will undoubtedly lead to the identiﬁca-
tion of many new transporter functions
and substrates in the coming years.
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Letter
Response to ‘The
Need for Speed’,
by Matsson et al.
Pedro Mendes,1,2,3,4
Stephen G. Oliver,5,6 and
Douglas B. Kell2,3,7,@,*
We do not really understand the continuing
failure of Matsson and colleagues to rec-
ognise where the crucial arguments lie. The
chief experimental technique of interest
varies transporter expression as an inde-
pendent variable, and measures the con-
sequent effects on ﬂuxes [1]. In a recent
example of this, Superti-Furga and col-
leagues knocked out the gene encoding
the SLC35F2 transporter, thereby abolish-
ing 99.5% of the uptake of an anticancer
drug called sepantronium bromide [2].
Thus any remaining transbilayer ﬂux would
be 0.5% at most, which we consider really
is negligible, and even that 0.5% is almost
certainly carried by other transporters
(OCTs) previously considered to be the
main transporters [2]. There is no dodging
these kinds of data, nor any of many other
self-consistent examples that we have
reviewed in our TiPS paper [3] and elsew-
where [4–13]. We urge readers to consider
these arguments in the round. They also
provide very simple explanations for why
there is a blood–brain barrier, for instance,
on the basis that it simply lacks the relevant
transporters, with any background
phospholipid bilayer diffusion clearly being
negligible. This is why it is seen as a
‘barrier’.
Some very brief comments of the letter of
Matsson and colleagues: (i) the ludicrously
high stirring rates for the propranolol and
verapamil values chosen (not of course
mimicked in the gut) mean that these val-
ues are complete outliers [3]; when the
fuller literature for multiple drugs is consid-
ered the median rate of drug uptake into
Caco-2 cells is almost two orders of mag-
nitude lower [14], and thus easily
accounted for solely by transporters; (ii)
the 42% is for ﬁve transporters, mimicking
the case used by Matsson et al., who
recognised that multiple transporters were
likely involved. There is no ‘mistake’.
(iii) The Haldane relation is a thermody-
namic relation and thus deals with state
variables; the numbers of membranes that
may be involved (and any mechanistic
considerations at all) are thus
completely irrelevant. Thermodynamics
is like that.
The ‘transporters-only’ view has many test-
able (and tested) predictions, all of which
have withstood scrutiny. It also admits the
possibility of selective drug targeting. With
attrition rates running at 92%, the pharma-
ceutical industry needs to ensure that it is
armed with the best possible intellectual
understanding of how drugs enter cells.
Hence the recent ‘call to arms’ for research
on drug transporters [15].
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Update
Although they choose not to cite any of
our prior literature, it seems that the ﬁrst
author does in fact believe that ‘Transport
proteins are important mediators of cellu-
lar drug inﬂux and efﬂux and play crucial
roles in drug distribution, disposition and
clearance’ [16].
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Forum
New Insights into the
Epithelial-to-
Mesenchymal
Transition in Cancer
Xiaolong Qi,1,4 Li Zhang,2,4
and Xiaojie Lu3,*
The role of the epithelial-to-mesen-
chymal transition (EMT) in cancer
progression is a long-debated issue.
Recent evidence shows that EMT is
not a prerequisite for cancer metas-
tasis, but does confer chemoresist-
ance. Future studies are needed to
proﬁle EMT events in different can-
cer types and under different cir-
cumstances to explore their
potentials as therapeutic targets.
Controversies over the roles of
EMT in cancer progression
The roles of EMT (Box 1, Figure 1) in cancer
progression have been long debated. A
popular proposal is that cancer cells
undergo EMT to facilitate invasion and dis-
semination, and then go through a reverse
process, termed the mesenchymal–epithe-
lial transition (MET), for clonal outgrowth at
metastatic sites [1]. However, this EMT–
MET proposal is mainly based on evidence
from manipulated expression of EMT-
inducing transcription factors (EMT-TFs)
or xenograft experiments [1,2]. Whether
these experiments can faithfully recapitu-
late the real role of spontaneous EMT in
cancer progression remains a question
because the artiﬁcially activated EMT-TFs
may have roles in metastasis beyond EMT
activation [2]. Other evidence that lends
support to the signiﬁcance of EMT in can-
cer metastasis includes the fact that EMT
can confer to cancer cells resistance to
apoptosis and can endow malignant epi-
thelial cells with cancer stem cell (CSC)-like
properties [3–5]. It is appealing to assume
that increased resistance to apoptosis may
help cancer cells survive the rigorous jour-
ney from primary sites to distance organs
and that CSC-like properties may facilitate
metastatic colonization. However, direct
evidence of the functionalities of naturally
occurring EMT in spontaneous cancer pro-
gression is lacking, due largely to the tech-
nological difﬁculties of distinguishing
mesenchymal cancer cells from surround-
ing stromal cells and of capturing and trac-
ing the transitory EMT process in vivo
during cancer metastasis. Therefore, con-
troversies still exist regarding the roles of
EMT in cancer progression.
New Insights into the Roles of
EMT in Cancer Progression
Recent evidence sheds new light on this
long-contested issue. To address the dif-
ﬁculties of tracing reversible EMT in vivo,
Fischer et al. [6] engineered cancer cells to
express a Cre-switchable ﬂuorescent
marker so that the expression of red ﬂuo-
rescent protein (RFP) can be switched to
green ﬂuorescent protein (GFP) upon the
activation of mesenchymal-speciﬁc
markers, such as ﬁbroblast-speciﬁc pro-
tein 1 (Fsp1) or vimentin. When cells har-
boring this system go through EMT, they
are switched from RFP+ to GFP+. This is
an irreversible tracing system, in that EMT
cells remain GFP+ even if they return to the
epithelial state afterwards. In two separate
mouse models of breast cancer with
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